ClinicalTrials.gg
Active, not recruitingNCT01874353Updated Jul 29, 2026Results posted

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

A Phase 3 interventional study of Olaparib 300mg tablets and Placebo to match olaparib 300mg in Platinum Sensitive, BRCA Mutated and Relapsed Ovarian Cancer, sponsored by AstraZeneca. Active, not recruiting at 126 sites in 17 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
327
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.

Enrollment
11th of 69
327 · median 97
Started
2013
with 1 other
Phase 3
16 of 69
2 open now
Primary completion
2016-09
later than 1 of 25 live
Registered
14th of 69
by date
Lead sponsor
21 of 69
AstraZeneca

Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 11th largest by enrollment, is one of 2 that started in 2013, is one of 16 in phase 3, reaches primary completion later than 1 of the 25 other live ones, and was the 14th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 130 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing olaparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

A Phase III, randomised, double-blind, placebo-controlled, multi-centre study to assess the efficacy of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary peritoneal and / or fallopian tube cancer) or high grade endometrioid cancer with BRCA mutations (documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)) who have responded following platinum based chemotherapy.

Read the detailed description

Comparison of olaparib against a placebo in patients with ovarian cancer whose cancer has already improved by taking platinum based chemotherapy. The patients must also have a fault in their DNA which codes for the BRCA protein. The BRCA protein helps mend broken DNA in the cells of the body; if this protein doesn't work properly it can increase the chance of getting cancer. The aim of this study is to see whether patients taking olaparib tablets last longer until their cancer gets worse, compared to those taking the placebo tablet. The study is also looking to see if there is an overall improvement to how long the patients survive whilst taking olaparib tablets compared to the placebo tablets; and the quality of their life whilst living with ovarian cancer.

03

Conditions studied

  • Platinum Sensitive
  • BRCA Mutated
  • Relapsed Ovarian Cancer
  • Following Complete or Partial Response to Platinum Based Chemotherapy

Browse trials for

Keywords

  • BRCA
  • Ovarian cancer
  • Chemotherapy
  • PARP Inhibitor
  • Platinum sensitive
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be ≥ 18 years of age.

    • Female patients with diagnosed high grade serous ovarian cancer (including primary peritoneal and / or fallopian tube cancer) or high grade endometrioid cancer.
    • Documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function).
    • Patients who have received at least 2 previous lines of platinum containing therapy prior to randomisation

For the penultimate chemotherapy course prior to enrolment on the study:

  • Patient defined as platinum sensitive after this treatment; defined as disease progression greater than 6 months after completion of their last dose of platinum chemotherapy

For the last chemotherapy course immediately prior to randomisation on the study:

  • Patients must be, in the opinion of the investigator, in response (partial or complete radiological response), or may have no evidence of disease (if optimal cytoreductive surgery was conducted prior to chemotherapy), and no evidence of a rising CA-125, following completion of this chemotherapy course
  • Patient must have received a platinum based chemotherapy regimen (e.g. carboplatin or cisplatin) and have received at least 4 cycles of treatment
  • Patients must be randomized within 8 weeks of their last dose of chemotherapy
  • Maintenance treatment is allowed at the end of the penultimate platinum regimen, including bevacizumab

Exclusion criteria

Exclusion Criteria:

  • Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  • BRCA 1 and/or BRCA2 mutations that are considered to be non detrimental (e.g., "Variants of uncertain clinical significance" or "Variant of unknown significance" or "Variant, favor polymorphism" or "benign polymorphism" etc.)
  • Patients who have had drainage of their ascites during the final 2 cycles of their last chemotherapy regimen prior to enrolment on the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
327 participants (actual)

Study arms

  • Experimental
    Olaparib 300mg tablets

    Taken orally twice daily

    Drug: Olaparib 300mg tablets

  • Placebo comparator
    Placebo tablets

    Taken orally twice daily

    Drug: Placebo to match olaparib 300mg

Interventions

  • 300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.

  • DrugPlacebo to match olaparib 300mg

    300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1)

    To determine the efficacy by progression free survival (PFS) (using investigator assessment according to modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1)) of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy.

    Time frame: Radiologic scans performed at baseline then every ~12 weeks up to 72 weeks, then every ~ 24 weeks thereafter until objective radiological disease progression. Assessed until 19 Sep 2016 DCO (16 Jan 2017 DCO for China Cohort); up to a maximum of 36 months.

Secondary outcomes

  1. Efficacy in Patients Following Platinum Based Chemotherapy by Assessment of Overall Survival

    To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy by assessment of overall survival (OS).

    Time frame: Survival assessed every 4 weeks until treatment discontinues, then every 12 weeks. Assessed until 03 Feb 2020 DCO; up to a maximum of 75 months.

  2. Efficacy in Patients Following Platinum Based Chemotherapy by Assessment of Time to Earliest Progression by RECIST or Cancer Antigen (CA-125) or Death

    To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy by assessment of time to earliest progression by RECIST or CA-125 or death.

    Time frame: CA-125 at baseline then every 4 wks. Radiologic scans at baseline then every ~12 wks up to 72 wks, then every ~ 24 wks until objective radiological disease progression. Assessed until 19Sep2016 DCO (16Jan2017 DCO for China Cohort); up to a max of 36 mths.

  3. Efficacy in Patients Following Platinum Based Chemotherapy by Assessment of Time From Randomization to Second Progression

    To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete response or partial response following first line platinum based chemotherapy by assessment of time from randomization up to second progression

    Time frame: Scans at baseline then every 12 wks for 72 wks, then every 24 wks until first progression. Assessments then per local practice every 12 wks until second progression. Assessed until 19Sep2016 DCO (16Jan2017 DCO for China Cohort); up to a max of 36 mths

  4. Change From Baseline in Health-Related Quality of Life (HRQoL) as Assessed by the the Trial Outcome Index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O)

    To compare the effects of olaparib maintenance monotherapy compared to placebo on Health-related Quality of Life (HRQoL) as assessed by the trial outcome index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy. The TOI ranges from 0-100 and a higher score indicates a higher HRQoL.

    Time frame: Questionnaires completed by patient at baseline, Day 29 and then every 12 weeks for 12 months. Assessed until 19 Sep 2016 DCO.

  5. Efficacy of Olaparib by Time to First Subsequent Therapy or Death (TFST)

    To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomization to first subsequent therapy or death (TFST).

    Time frame: Time elapsed from randomization to first subsequent therapy or death. Assessed every 12 weeks following treatment discontinuation. Assessed until 03 Feb 2020 DCO; up to a maximum of 75 months.

  6. Efficacy of Olaparib by Time to Second Subsequent Therapy or Death (TSST)

    To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomization to second subsequent therapy or death (TSST).

    Time frame: Time elapsed from randomization to second subsequent therapy or death. Assessed every 12 weeks following treatment discontinuation. Assessed until 03 Feb 2020 DCO; up to a maximum of 75 months.

  7. Efficacy of Olaparib by Time From Randomization to Study Treatment Discontinuation or Death (TDT)

    To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomization to study treatment discontinuation or death (TDT).

    Time frame: Time elapsed from randomization to study treatment discontinuation or death. Assessed until 03 Feb 2020 DCO; up to a maximum of 75 months.

  8. Efficacy in Patients With a Deleterious or Suspected Deleterious Variant in Either of the BRCA Genes by Assessment of PFS.

    To assess efficacy of olaparib in patients identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (gene sequencing and large rearrangement analysis).

    Time frame: Radiologic scans performed at baseline then every ~12 weeks for the first 72 weeks, then every ~24 weeks thereafter, assessed until disease progression. Assessed until 19 Sep 2016 DCO.

  9. To Determine the Exposure to Olaparib by Pharmacokinetic Analysis

    To determine the exposure to olaparib in patients receiving olaparib maintenance monotherapy

    Time frame: Pharmacokinetics sampling to be performed in a subset of patients. Sampling times: Day 1 pre-dose & 1 hour; Day 15 pre-dose & 1 hour; Day 29 pre-dose. Assessed until 19 Sep 2016 DCO.

07

Results

Posted Feb 7, 2018
Limitations and caveats
The outbreak of the COVID-19 pandemic shortly before the final OS DCO (03 February 2020) was not judged to meaningfully impact the overall quality of the study, including the conduct, data, and interpretation of results.

Participant flow

Global Cohort: First patient screened: 03 Sep 2013; last patient screened on 21 Nov 2014. 602 patients screened across 119 centres in 16 countries; 295 were randomized. Results are reported for analysis of PFS (DCO: 19 Sep 2016) and OS (DCO: 03 Feb 2020). China Cohort: First patient enrolled: 07 Apr 2015; last patient enrolled: 30 Oct 2015. 127 patients screened across 16 sites; 32 were randomized. Results are reported for analysis of PFS (DCO: 16 Jan 2017) and OS (DCO: 03 Feb 2020).

Participant flow — Overall Study
MilestoneOlaparib 300mg Tablets (Global Cohort)Placebo Tablets (Global Cohort)Olaparib 300mg Tablets (China Cohort)Placebo Tablets (China Cohort)
Started196992210
Completed692673
Not completed12773157
Withdrew: One patient was unblinded and one patient was randomised in error2000
Withdrew: Lost to follow-up2220
Withdrew: Death11060137
Withdrew: Withdrawal by subject131100

Outcome measures

PrimaryProgression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1)

To determine the efficacy by progression free survival (PFS) (using investigator assessment according to modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1)) of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy.

Time frame:
Radiologic scans performed at baseline then every ~12 weeks up to 72 weeks, then every ~ 24 weeks thereafter until objective radiological disease progression. Assessed until 19 Sep 2016 DCO (16 Jan 2017 DCO for China Cohort); up to a maximum of 36 months.
Reported as:
Median · Months
Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1)
MonthsOlaparib 300mg Tablets (Global Cohort)Placebo Tablets (Global Cohort)Olaparib 300mg Tablets (China Cohort)Placebo Tablets (China Cohort)
Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1)19.1 (16.3 to 25.7)5.5 (5.2 to 5.8)13.8 (6.5 to 16.6)5.5 (2.7 to NA)
Statistical analysis
  • Olaparib 300mg Tablets (Global Cohort) vs Placebo Tablets (Global Cohort) · Regression, Cox · p = <0.0001 (Determined using a log-rank test stratified by response to previous platinum chemotherapy and time to disease progression in the penultimate platinum based chemotherapy prior to enrolment) · Hazard ratio (hr): 0.30 · 95% CI 0.22 to 0.41A hazard ratio \< 1 favours olaparib
  • Olaparib 300mg Tablets (China Cohort) vs Placebo Tablets (China Cohort) · Regression, Cox · Hazard ratio (hr): 0.44 · 95% CI 0.17 to 1.19A hazard ratio \< 1 favours olaparib
SecondaryEfficacy in Patients Following Platinum Based Chemotherapy by Assessment of Overall Survival

To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy by assessment of overall survival (OS).

Time frame:
Survival assessed every 4 weeks until treatment discontinues, then every 12 weeks. Assessed until 03 Feb 2020 DCO; up to a maximum of 75 months.
Reported as:
Median · Months
Efficacy in Patients Following Platinum Based Chemotherapy by Assessment of Overall Survival
MonthsOlaparib 300mg Tablets (Global Cohort)Placebo Tablets (Global Cohort)Olaparib 300mg Tablets (China Cohort)Placebo Tablets (China Cohort)
Efficacy in Patients Following Platinum Based Chemotherapy by Assessment of Overall Survival51.7 (41.5 to 59.1)38.8 (31.4 to 48.6)41.7 (17.6 to NA)36.4 (13.2 to NA)
Statistical analysis
  • Olaparib 300mg Tablets (Global Cohort) vs Placebo Tablets (Global Cohort) · Regression, Cox · p = 0.0537 (Determined using a log-rank test stratified by response to previous platinum chemotherapy and time to disease progression in the penultimate platinum based chemotherapy prior to enrolment) · Hazard ratio (hr): 0.74 · 95% CI 0.54 to 1.00A hazard ratio \<1 favours olaparib
  • Olaparib 300mg Tablets (China Cohort) vs Placebo Tablets (China Cohort) · Regression, Cox · Hazard ratio (hr): 0.93 · 95% CI 0.38 to 2.49A hazard ratio \<1 favours olaparib
SecondaryEfficacy in Patients Following Platinum Based Chemotherapy by Assessment of Time to Earliest Progression by RECIST or Cancer Antigen (CA-125) or Death

To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy by assessment of time to earliest progression by RECIST or CA-125 or death.

Time frame:
CA-125 at baseline then every 4 wks. Radiologic scans at baseline then every ~12 wks up to 72 wks, then every ~ 24 wks until objective radiological disease progression. Assessed until 19Sep2016 DCO (16Jan2017 DCO for China Cohort); up to a max of 36 mths.
Reported as:
Median · Months
Efficacy in Patients Following Platinum Based Chemotherapy by Assessment of Time to Earliest Progression by RECIST or Cancer Antigen (CA-125) or Death
MonthsOlaparib 300mg Tablets (Global Cohort)Placebo Tablets (Global Cohort)Olaparib 300mg Tablets (China Cohort)Placebo Tablets (China Cohort)
Efficacy in Patients Following Platinum Based Chemotherapy by Assessment of Time to Earliest Progression by RECIST or Cancer Antigen (CA-125) or Death16.9 (14.6 to 22.3)4.9 (3.7 to 5.6)12.9 (5.9 to 14.0)3.7 (1.0 to 7.4)
Statistical analysis
  • Olaparib 300mg Tablets (Global Cohort) vs Placebo Tablets (Global Cohort) · Regression, Cox · p = <0.0001 (Determined using a log-rank test stratified by response to previous platinum chemotherapy and time to disease progression in the penultimate platinum based chemotherapy prior to enrolment) · Hazard ratio (hr): 0.30 · 95% CI 0.23 to 0.41A hazard ratio \< 1 favours olaparib
  • Olaparib 300mg Tablets (China Cohort) vs Placebo Tablets (China Cohort) · Regression, Cox · Hazard ratio (hr): 0.41 · 95% CI 0.18 to 1.03A hazard ratio \<1 favours olaparib
SecondaryEfficacy in Patients Following Platinum Based Chemotherapy by Assessment of Time From Randomization to Second Progression

To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete response or partial response following first line platinum based chemotherapy by assessment of time from randomization up to second progression

Time frame:
Scans at baseline then every 12 wks for 72 wks, then every 24 wks until first progression. Assessments then per local practice every 12 wks until second progression. Assessed until 19Sep2016 DCO (16Jan2017 DCO for China Cohort); up to a max of 36 mths
Reported as:
Median · Months
Efficacy in Patients Following Platinum Based Chemotherapy by Assessment of Time From Randomization to Second Progression
MonthsOlaparib 300mg Tablets (Global Cohort)Placebo Tablets (Global Cohort)Olaparib 300mg Tablets (China Cohort)Placebo Tablets (China Cohort)
Efficacy in Patients Following Platinum Based Chemotherapy by Assessment of Time From Randomization to Second ProgressionNA (24.1 to NA)18.4 (15.4 to 22.8)NA (NA to NA)17.3 (6.0 to 17.3)
Statistical analysis
  • Olaparib 300mg Tablets (Global Cohort) vs Placebo Tablets (Global Cohort) · Regression, Cox · p = 0.0002 (Determined using a log-rank test stratified by response to previous platinum chemotherapy and time to disease progression in the penultimate platinum based chemotherapy prior to enrolment) · Hazard ratio (hr): 0.50 · 95% CI 0.34 to 0.72A hazard ratio \< 1 favours olaparib
  • Olaparib 300mg Tablets (China Cohort) vs Placebo Tablets (China Cohort) · Regression, Cox · Hazard ratio (hr): 0.84 · 95% CI 0.22 to 3.97A hazard ratio \< 1 favours olaparib
SecondaryChange From Baseline in Health-Related Quality of Life (HRQoL) as Assessed by the the Trial Outcome Index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O)

To compare the effects of olaparib maintenance monotherapy compared to placebo on Health-related Quality of Life (HRQoL) as assessed by the trial outcome index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy. The TOI ranges from 0-100 and a higher score indicates a higher HRQoL.

Time frame:
Questionnaires completed by patient at baseline, Day 29 and then every 12 weeks for 12 months. Assessed until 19 Sep 2016 DCO.
Reported as:
Least squares mean · Change in TOI over 12 months
Change From Baseline in Health-Related Quality of Life (HRQoL) as Assessed by the the Trial Outcome Index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O)
Change in TOI over 12 monthsOlaparib 300mg Tablets (Global Cohort)Placebo Tablets (Global Cohort)
Change From Baseline in Health-Related Quality of Life (HRQoL) as Assessed by the the Trial Outcome Index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O)-2.90 (-4.131 to -1.673)-2.87 (-4.643 to -1.097)
Statistical analysis
  • Olaparib 300mg Tablets (Global Cohort) vs Placebo Tablets (Global Cohort) · Mixed Models Analysis · p = 0.9765 · Mean difference (final values): -0.03 · 95% CI -2.191 to 2.126Fixed effects for treatment, visit and baseline TOI with the treatment by visit and baseline TOI by visit interaction. Random patient effect.
SecondaryEfficacy of Olaparib by Time to First Subsequent Therapy or Death (TFST)

To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomization to first subsequent therapy or death (TFST).

Time frame:
Time elapsed from randomization to first subsequent therapy or death. Assessed every 12 weeks following treatment discontinuation. Assessed until 03 Feb 2020 DCO; up to a maximum of 75 months.
Reported as:
Median · Months
Efficacy of Olaparib by Time to First Subsequent Therapy or Death (TFST)
MonthsOlaparib 300mg Tablets (Global Cohort)Placebo Tablets (Global Cohort)Olaparib 300mg Tablets (China Cohort)Placebo Tablets (China Cohort)
Efficacy of Olaparib by Time to First Subsequent Therapy or Death (TFST)27.4 (22.6 to 31.1)7.2 (6.3 to 8.5)13.9 (9.1 to 15.9)5.5 (1.4 to 18.4)
Statistical analysis
  • Olaparib 300mg Tablets (Global Cohort) vs Placebo Tablets (Global Cohort) · Regression, Cox · p = <0.0001 (Determined using a log-rank test stratified by response to previous platinum chemotherapy and time to disease progression in the penultimate platinum based chemotherapy prior to enrolment) · Hazard ratio (hr): 0.37 · 95% CI 0.28 to 0.48A hazard ratio \< 1 favours olaparib
  • Olaparib 300mg Tablets (China Cohort) vs Placebo Tablets (China Cohort) · Regression, Cox · Hazard ratio (hr): 0.47 · 95% CI 0.21 to 1.08A hazard ratio \< 1 favours olaparib
SecondaryEfficacy of Olaparib by Time to Second Subsequent Therapy or Death (TSST)

To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomization to second subsequent therapy or death (TSST).

Time frame:
Time elapsed from randomization to second subsequent therapy or death. Assessed every 12 weeks following treatment discontinuation. Assessed until 03 Feb 2020 DCO; up to a maximum of 75 months.
Reported as:
Median · Months
Efficacy of Olaparib by Time to Second Subsequent Therapy or Death (TSST)
MonthsOlaparib 300mg Tablets (Global Cohort)Placebo Tablets (Global Cohort)Olaparib 300mg Tablets (ChinaCohort)Placebo Tablets (China Cohort)
Efficacy of Olaparib by Time to Second Subsequent Therapy or Death (TSST)35.8 (29.4 to 43.9)18.9 (15.5 to 21.5)19.0 (10.1 to 32.8)26.4 (6.3 to 36.0)
Statistical analysis
  • Olaparib 300mg Tablets (Global Cohort) vs Placebo Tablets (Global Cohort) · Regression, Cox · p = <0.0001 (Determined using a log-rank test stratified by response to previous platinum chemotherapy and time to disease progression in the penultimate platinum based chemotherapy prior to enrolment) · Hazard ratio (hr): 0.51 · 95% CI 0.39 to 0.68A hazard ratio \< 1 favours olaparib
  • Olaparib 300mg Tablets (ChinaCohort) vs Placebo Tablets (China Cohort) · Regression, Cox · Hazard ratio (hr): 0.81 · 95% CI 0.37 to 1.85A hazard ratio \< 1 favours olaparib
SecondaryEfficacy of Olaparib by Time From Randomization to Study Treatment Discontinuation or Death (TDT)

To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomization to study treatment discontinuation or death (TDT).

Time frame:
Time elapsed from randomization to study treatment discontinuation or death. Assessed until 03 Feb 2020 DCO; up to a maximum of 75 months.
Reported as:
Median · Months
Efficacy of Olaparib by Time From Randomization to Study Treatment Discontinuation or Death (TDT)
MonthsOlaparib 300mg Tablets (Global Cohort)Placebo Tablets (Global Cohort)Olaparib 300mg Tablets (China Cohort)Placebo Tablets (China Cohort)
Efficacy of Olaparib by Time From Randomization to Study Treatment Discontinuation or Death (TDT)19.4 (14.9 to 25.9)5.6 (5.0 to 6.8)13.4 (6.3 to 16.5)4.7 (1.3 to 11.1)
Statistical analysis
  • Olaparib 300mg Tablets (Global Cohort) vs Placebo Tablets (Global Cohort) · Regression, Cox · p = <0.0001 (Determined using a log-rank test stratified by response to previous platinum chemotherapy and time to disease progression in the penultimate platinum based chemotherapy prior to enrolment) · Hazard ratio (hr): 0.37 · 95% CI 0.28 to 0.49A hazard ratio \< 1 favours olaparib
  • Olaparib 300mg Tablets (China Cohort) vs Placebo Tablets (China Cohort) · Regression, Cox · Hazard ratio (hr): 0.45 · 95% CI 0.20 to 1.04A hazard ratio \< 1 favours the Olaparib arm
SecondaryEfficacy in Patients With a Deleterious or Suspected Deleterious Variant in Either of the BRCA Genes by Assessment of PFS.

To assess efficacy of olaparib in patients identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (gene sequencing and large rearrangement analysis).

Time frame:
Radiologic scans performed at baseline then every ~12 weeks for the first 72 weeks, then every ~24 weeks thereafter, assessed until disease progression. Assessed until 19 Sep 2016 DCO.
Reported as:
Median · Months
Efficacy in Patients With a Deleterious or Suspected Deleterious Variant in Either of the BRCA Genes by Assessment of PFS.
MonthsOlaparib 300mg Tablets (Global Cohort)Placebo Tablets (Global Cohort)
Efficacy in Patients With a Deleterious or Suspected Deleterious Variant in Either of the BRCA Genes by Assessment of PFS.19.3 (16.5 to 27.3)5.5 (5.0 to 5.8)
Statistical analysis
  • Olaparib 300mg Tablets (Global Cohort) vs Placebo Tablets (Global Cohort) · Regression, Cox · p = <0.0001 (Determined using a log-rank test stratified by response to previous platinum chemotherapy and time to disease progression in the penultimate platinum based chemotherapy prior to enrolment) · Hazard ratio (hr): 0.30 · 95% CI 0.22 to 0.40A hazard ratio \< 1 favours olaparib
SecondaryTo Determine the Exposure to Olaparib by Pharmacokinetic Analysis

To determine the exposure to olaparib in patients receiving olaparib maintenance monotherapy

Time frame:
Pharmacokinetics sampling to be performed in a subset of patients. Sampling times: Day 1 pre-dose & 1 hour; Day 15 pre-dose & 1 hour; Day 29 pre-dose. Assessed until 19 Sep 2016 DCO.
Reported as:
Geometric mean · mcg/mL
To Determine the Exposure to Olaparib by Pharmacokinetic Analysis
mcg/mLOlaparib 300mg Tablets
Day 1 - Pre-doseNA ± NA
Day 1 - 1 hour3.26 ± 312.2
Day 15 - Pre-dose0.92 ± 95.5
Day 15 - 1 hour5.12 ± 61.8
Day 29 - Pre-dose0.94 ± 179.0

Adverse events

Collected over Includes adverse events with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of olaparib/placebo.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olaparib 300 Tablets (Global Cohort)116/196 (59.2%)50/195 (25.6%)192/195 (98.5%)
Placebo Tablets (Global Cohort)65/99 (65.7%)8/99 (8.1%)91/99 (91.9%)
Olaparib 300 Tablets (China Cohort)13/22 (59.1%)5/22 (22.7%)21/22 (95.5%)
Placebo Tablets (China Cohort)7/10 (70%)1/10 (10%)10/10 (100%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventOlaparib 300 Tablets (Global Cohort)Placebo Tablets (Global Cohort)Olaparib 300 Tablets (China Cohort)Placebo Tablets (China Cohort)
GastroenteritisInfections and infestations0/1950/990/221/10
AnaemiaBlood and lymphatic system disorders8/1950/992/220/10
NeutropeniaBlood and lymphatic system disorders1/1950/991/220/10
Food poisoningGastrointestinal disorders0/1950/991/220/10
White blood cell count decreasedInvestigations0/1950/991/220/10
LeukopeniaBlood and lymphatic system disorders0/1950/991/220/10
Haemoglobin decreasedInvestigations0/1950/991/220/10
Neutrophil count decreasedInvestigations0/1950/991/220/10
Abdominal painGastrointestinal disorders4/1950/990/220/10
Intestinal obstructionGastrointestinal disorders4/1951/990/220/10
Most frequent other events
Showing 10 of 79
Most frequent other events
EventOlaparib 300 Tablets (Global Cohort)Placebo Tablets (Global Cohort)Olaparib 300 Tablets (China Cohort)Placebo Tablets (China Cohort)
NauseaGastrointestinal disorders148/19535/9918/221/10
AnaemiaBlood and lymphatic system disorders83/1959/997/220/10
VomitingGastrointestinal disorders77/19520/998/221/10
FatigueGeneral disorders75/19515/997/222/10
Decreased appetiteMetabolism and nutrition disorders44/19511/998/222/10
DiarrhoeaGastrointestinal disorders67/19520/994/220/10
Upper respiratory tract infectionInfections and infestations17/1956/997/222/10
AstheniaGeneral disorders62/19527/992/220/10
Abdominal painGastrointestinal disorders53/19531/993/220/10
Abdominal distensionGastrointestinal disorders13/1957/993/223/10

Baseline characteristics

Global Cohort: 196 Olaparib, 99 Placebo China Cohort: 22 Olaparib, 10 Placebo

Age, Continuous
Age, Continuous(Years)Olaparib 300mg TabletsPlacebo TabletsTotal
Global Cohort57.0 ± 9.256.6 ± 8.956.9 ± 9.09
China Cohort50.6 ± 8.4247.4 ± 9.2949.6 ± 8.68
Age, Customized
Age, Customized(Participants)Olaparib 300mg TabletsPlacebo TabletsTotal
Global Cohort — <50382563
Global Cohort — >=50-<6511852170
Global Cohort — >=65402262
China Cohort — <5011718
China Cohort — >=50-<6510212
China Cohort — >=65112
Sex: Female, Male
Sex: Female, Male(Participants)Olaparib 300mg TabletsPlacebo TabletsTotal
Global Cohort — Female19699295
Global Cohort — Male000
China Cohort — Female221032
China Cohort — Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Olaparib 300mg TabletsPlacebo TabletsTotal
Global Cohort — Hispanic or Latino10111
Global Cohort — Not Hispanic or Latino18698284
Global Cohort — Unknown or Not Reported000
China Cohort — Hispanic or Latino000
China Cohort — Not Hispanic or Latino221032
China Cohort — Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Olaparib 300mg TabletsPlacebo TabletsTotal
Global Cohort — WHITE17391264
Global Cohort — BLACK OR AFRICAN AMERICAN101
Global Cohort — AMERICAN INDIAN OR ALASKA NATIVE000
Global Cohort — ASIAN22729
Global Cohort — NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER000
Global Cohort — OTHER011
China Cohort — WHITE000
China Cohort — BLACK OR AFRICAN AMERICAN000
China Cohort — AMERICAN INDIAN OR ALASKA NATIVE000
China Cohort — ASIAN221032
China Cohort — NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER000
China Cohort — OTHER000
08

Study locations

126 sites

Showing the first 100 of 126 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ledermann JA, Lortholary A, Penson RT, Asher R, Gebski V, Provencher D, Bruchim I, Huzarski T, Barretina-Ginesta MP, Pipitone S, Mileshkin L, Colombo N, Park-Simon TW, Matsumoto K, Boere I, Mikheeva O, Kim JW, Girotto G, Vergote I, Carter D, Lowe ES, Pujade-Lauraine E. Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial. Int J Gynecol Cancer. 2026 May;36(5):104556. doi: 10.1016/j.ijgc.2026.104556. Epub 2026 Mar 2. PubMed 41861615 ↗
  • Barnicle A, Ray-Coquard I, Rouleau E, Cadoo K, Simpkins F, Aghajanian C, Leary A, Poveda A, Lheureux S, Pujade-Lauraine E, You B, Ledermann J, Matulonis U, Gourley C, Timms KM, Lai Z, Hodgson DR, Elks CE, Dearden S, Egile C, Lao-Sirieix P, Harrington EA, Brown JS. Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib. Genome Med. 2024 Dec 18;16(1):145. doi: 10.1186/s13073-024-01413-5. PubMed 39695768 ↗
  • Frenel JS, Kim JW, Aryal N, Asher R, Berton D, Vidal L, Pautier P, Ledermann JA, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Colombo N, Park-Simon TW, Tamura K, Sonke GS, Freimund AE, Lee CK, Pujade-Lauraine E. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial. Ann Oncol. 2022 Oct;33(10):1021-1028. doi: 10.1016/j.annonc.2022.06.011. Epub 2022 Jun 27. PubMed 35772665 ↗
  • Tattersall A, Ryan N, Wiggans AJ, Rogozinska E, Morrison J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev. 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4. PubMed 35170751 ↗
  • Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 May;22(5):620-631. doi: 10.1016/S1470-2045(21)00073-5. Epub 2021 Mar 18. PubMed 33743851 ↗
  • Tjokrowidjaja A, Lee CK, Friedlander M, Gebski V, Gladieff L, Ledermann J, Penson R, Oza A, Korach J, Huzarski T, Manso L, Pisano C, Asher R, Lord SJ, Kim SI, Lee JY, Colombo N, Park-Simon TW, Fujiwara K, Sonke G, Vergote I, Kim JW, Pujade-Lauraine E. Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. Eur J Cancer. 2020 Nov;139:59-67. doi: 10.1016/j.ejca.2020.08.021. Epub 2020 Sep 23. PubMed 32977221 ↗
  • Friedlander M, Gebski V, Gibbs E, Davies L, Bloomfield R, Hilpert F, Wenzel LB, Eek D, Rodrigues M, Clamp A, Penson RT, Provencher D, Korach J, Huzarski T, Vidal L, Salutari V, Scott C, Nicoletto MO, Tamura K, Espinoza D, Joly F, Pujade-Lauraine E. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncol. 2018 Aug;19(8):1126-1134. doi: 10.1016/S1470-2045(18)30343-7. Epub 2018 Jul 17. PubMed 30026002 ↗
  • Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25. PubMed 28754483 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Sep 2016, 36 months.

Results were first posted in Feb 2018, 1 year 4 months after primary completion.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 36 months is below that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2013
First posted
Jun 11, 2013
StartActual
Sep 3, 2013
Primary completionActual
Sep 19, 2016
CompletionEst.
Dec 31, 2026
Results first posted
Feb 7, 2018
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01874353
Lead sponsor
AstraZeneca
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT), Myriad Genetic Laboratories, Inc., Merck Sharp & Dohme LLC
Responsible party
Sponsor
First posted
Jun 11, 2013
Start date
Sep 3, 2013
Primary completion
Sep 19, 2016
Completion
Dec 31, 2026 (estimated)
Results posted
Feb 7, 2018
Last update
Jul 29, 2026

Study contacts

Professor E Pujade-Lauraine, MD, PhD
principal investigator · Universite de Paris Descartes, France

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion